Da Silva AN, Tepper SJ. Acute treatment of migraines. CNS Drugs. 2012;26(10):823–839.

Lipton RB et al. Stratified care vs step care strategies for migraine. The Disability in Strategies of Care (DISC)

study: a randomized trial. JAMA. 2000;284(20):2599–2605.

Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs. 2010;70(12):1505–1518.

Tepper SJ et al. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59(7):1084–1088.

Ferrari MD. Migraine. Lancet. 1998;351:1043.

Derry CJ et al. Sumatriptan (all routes of administration) for acute migraine attacks in adults-overview of

Cochrane reviews. Cochrane Database Syst Rev. 2014;5:CD009108.

Tepper SJ et al. Oralsumatriptan for the acute treatment of probable migraine: first randomized, controlled study.

Headache. 2006;46:115–124.

Touchon J et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute

treatment of migraine. Neurology. 1996;47:361.

Winner P et al. A double-blind study of subcutaneous dihydroergotamine vs. subcutaneous sumatriptan in the

treatment of acute migraine. Arch Neurol. 1996;53:180.

Boureau F et al. A clinical comparison of sumatriptan nasalspray and dihydroergotamine nasalspray in the acute

treatment of migraine. Int J Clin Pract. 2000;54(5):281–286.

Chen L, Ashcroft D. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of

migraine. Headache. 2007;47:1169–1177.

Mathew NT et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache.

2003;43(3):214–222.

Pini LA et al. Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan

in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. J Headache

Pain. 2012;13:669–675.

Tepper SJ et al. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs

100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS Study): a comparative

randomized clinical trial across multiple attacks. Headache. 2015;55(5):621–635.

Cady RK et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of

sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). Headache.

2015;55:88–100.

Landy SH et al. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with

subcutaneous sumatriptan. Headache. 2013;53(1):118–125.

Welch KM et al. Tolerability of sumatriptan: clinical trials and post-marketing experience [published correction

appears in Cephalalgia. 2001;21:164]. Cephalalgia. 2000;20:687.

Shimizu M et al. Sumatriptan provokes coronary artery spasm in patients with variant angina: possible involvement

of serotonin 1B receptor. Int J Cardiol. 2007;114:188–194.

100.

101.

102.

103.

104.

105.

Stillman MJ et al. QT prolongation, torsade de pointes, myocardial ischemia from coronary vasospasm, and

headache medications. Part 2: review of headache medications, drug-drug interactions, QTc prolongation, and

other arrhythmias. Headache. 2013;53:217–224.

Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs. 1998;55:889.

Food and Drug Administration. Public health advisory: combined use of 5-hydroxytryptamine receptor agonists

(triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephirne reuptake

inhibitors (SNRIs) may result in life-threatening serotonin syndrome. Rockville, MD; 2006.

Ferrari MD et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of

53 trials. Lancet. 2001;358:1668.

Becker WJ. Acute migraine treatment in adults. Headache. 2015;55:778–793.

Ferrari MD et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a metaanalysis of 53 trials. Cephalalgia. 2002;22:633–658.

Spierings EL et al. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind,

randomized, parallel-group, optimum-dose comparison. Arch Neurol. 2001;58(6):944–950.

Thorlund K et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment

comparison meta-analysis. Cephalalgia. 2014;34(4):258–267.

Savi L et al. Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with

moderate-to-severe migraine. Drug Des Devel Ther. 2014;8:983–992.

Goadsby PJ et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand.

2007;115:34–40.

Williams P, Reeder CE. Cost-effectiveness of alomotriptan and rizatriptan in the treatment of acute migraine. Clin

Ther. 2003;25:2903–2919.

Williams P, Reeder CE. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment

of acute migraine using a composite efficacy/tolerability end point. J Manag Care Pharm. 2004;10:259–265.

Sandrini G et al. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment

of migraine. Int J Clin Pract. 2005;59:1356–1365.

Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug–drug interactions. Headache.

2007;47:266–269.

Rolan PE. Drug interactions with triptans. Which are clinically significant? CNS Drugs. 2012;26:949–957.

Buchan P et al. Frovatriptan: a review of drug-drug interactions. Headache. 2002;42(Suppl 2):S63–S73.

Fleishaker JC et al. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol.

2003;43:423–427.

Wells RE et al. Identifying the factors underlying discontinuation of triptans. Headache. 2014;54(2):278–289.

Serrano D et al. Effects of switching acute treatment on disability in migraine patients using triptans. Headache.

2013;53:1415–1429.

Buse DC et al. Adding additional acute medications to a triptan regimen for migraine and observed changes in

headache-related disability: results from the American Migraine Prevalence and Prevention (AMPP) Study.

Headache. 2015;55:825–839.

Dahlof C, Maassen VanDenBrink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan-basic

science in relation to migraine treatment. Headache. 2012;52:707–714.

Silberstein SD, Hargreaves RJ. The history and pharmacology of ergotamine and dihydroergotamine. In: Diener

HC, ed. Drug Treatment of Migraine and Other Frequent Headaches. Basel, Switzerland: Karger Press;

2000:52–65.

Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraines. In: Olesen J et al, eds. The

Headaches. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:459.

Ziegler D et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44:447–

453.

Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Arch Neurol. 1996;53:1285–

1291.

Winner P et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the

treatment of acute migraine. Arch Neurol. 1996;53:180–184.

Aurora SK et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of

migraine. Headache. 2011;51:507–517.

Shrewsbury SB et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel

(Tempo) inhaler. Headache. 2007;48:355–367.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

Banhidy F et al. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth.

Br J Clin Pharmacol. 2007;64:510–516.

Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.

Headache. 2006;46(Suppl 4):S171–S181.

Friedman BW et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of

acute migraine. Ann Emerg Med. 2008;52(4):399–406.

Friedman BW et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg

Med. 2011;57(5):475–482.

Whyte C et al. Expert opinion. Rescue me: rescue medication for migraine. Headache. 2010;50:307.

Goldstein J et al. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine:

results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study.

Headache. 2006;46:444–453.

Rabbie R et al. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane

Database Syst Rev. 2013;4:CD008039.

Dib M et al; Bi-Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double-blind

randomized clinical trial. Neurology. 2002;58(11):1660–1665.

Beithon J et al. Institute for Clinical Symptoms Improvement. Diagnosis and Treatment of Headache.

https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_neurological_gJanuary 2013.

Schurks M. Dihydroergotamine: role in the treatment of migraine. Expert Opin Drug Metab Toxicol.

2009;5:1141.

Tanen DA et al. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment

of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003;41:847.

Friedman BW et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department.

Neurology. 2007;69(22):2038–2044.

Colman I et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised

controlled trials for preventing recurrence. BMJ. 2008;336:1359.

Goadsby PJ et al. Migraine-current understanding and treatment. N EnglJ Med. 2002;346:257.

Ramadan NM et al. Evidence-based guidelines for migraine headache in the primary care setting:

pharmacological management for prevention of migraine. US Headache Consortium, American Academy of

Neurology. https://www.aan.com/Guidelines/ Accessed May 26, 2015.

Fenstermacher N et al. Pharmacological prevention of migraine. BMJ. 2011;342:583.

Silberstein SD et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention

in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the

American Headache Society. Neurology. 2012;78:1337–1345.

Shamliyan TA et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med.

2013;28(9):1225–1237.

Wang DW et al. Propranolol blocks cardiac and neuronal voltage-gated sodium channels. Front Pharmacol.

2010;1(144):1–12.

Casucci G et al. Central mechanism of action of antimigraine prophylactic drugs. Neurol Sci. 2008;29(Suppl

1):S123–S126.

Ayata C et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59:652–

661.

Min JH et al. The effect of propranolol on cerebrovascular reactivity to visual stimulation in migraine. J Neurol

Sci. 2011;305(1–2):136–138.

Rao BS et al. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol

India. 2000;48;223–226.

Diener HC et al. A comparative study of oral acetylsalicylic acid and metoprolol for the prophylactic treatment

of migraine: a randomized, controlled, double-blind, parallel group phase III study. Cephalalgia. 2001;21:120–

128.

Schellenberg R et al. Nebivolol and metoprolol for treating migraine: an advance on β-blocker treatment?

Headache. 2008;48:118–125.

Hansen JM et al. Distinctive anatomical and physiological features of migraine aura revealed by 18 years of

recording. Brain. 2013;136:3589–3595.

Hansen JM et al. Variability of clinical features in attacks of migraine with aura. Cephalalgia. 2016;36(3):216–

133.

134.

135.

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

153.

154.

155.

156.

157.

158.

159.

224.

Schankin CJ et al. The relation between migraine, typical migraine aura and “visual snow”. Headache.

2014;54:957–966.

Hansen JM et al. Migraine headache is present in the aura phase. A prospective study. Neurology.

2012;79:2044–2049.

Cole JW, Kittner SJ. Meta-analysis of results from case control and cohort studies finds that migraine is

associated with approximately twice the risk of ischaemic stroke. Evid Based Med. 2010;15:193.

Schurks M et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ.

2009;339:b3914.

Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of

migraine. Lancet Neurol. 2010;9:285.

Finnerup NB et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain.

2005;118(3):289–305.

Smitherman TA et al. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther.

2010;17(5):462–469.

Liang J et al. Blockade of Nav

1.8 currents in nociceptive trigeminal neurons contributes to antitrigeminovascular nociceptive effect of amitriptyline. Neurol Med. 2014;16:308–321.

Pringsheim T et al. Selective decrease in serotonin synthesis rate in rat brainstem raphe nuclei following chronic

administration of low doses of amitriptyline: an effect compatible with an anti-migraine effect. Cephalalgia.

2003;23:367.

Moras K, Nischal H. Impact of amitriptyline on migraine disability assessment score. J Clin Diagn Res.

2014;8(9):KC01–KC02.

Kalita J et al. Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. Acta Neurol

Scand. 2013;128:65–72.

Dodick DW et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized,

double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;31(3):542–

559.

Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or

in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110:979–984.

Afshari D et al. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine

prophylaxis. Int J Neurosci. 2012;122(2):60–68.

Shaygannejad V et al. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a

randomized blinded crossover study. Headache. 2006;46:642–648.

Linde M et al. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev.

2013;6:CD010610.

Wenzel RG et al. Topiramate for migraine prevention. Pharmacotherapy. 2006;26:375.

Silberstein SD et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without

aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006;28(7):1002–

1011.

Brandes JL et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965–

973.

Diener HC et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as

an active control. J Neurol. 2004;251(8):943–950.

Silberstein S et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of

life and other efficacy measures. Headache. 2009;49:1153–1162.

Freitag FG et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Neurology. 2002;58(11):1652–1659.

Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without

aura. Arch Neurol. 1997;54:1141.

Meador KJ et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med.

2009;360:1597.

Gerstner T et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J

Gastroenterol. 2007;42:39–48.

Mathew NT et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119–128.

Tronvik E et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker. A randomized

160.

161.

162.

163.

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

174.

175.

176.

177.

178.

179.

180.

181.

182.

183.

184.

185.

186.

187.

188.

189.

controlled trial. JAMA. 2003;289(1):65–69.

Hauge AW et al. Effects of tonabersat on migraine with aura: a randomized, double-blind, placebo-controlled

crossover study. Lancet Neurol. 2009;8:718–723.

Chan WN et al. Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)-3,4-dihydro-2,2-dimethyl2H-benzo[b]pyran-3S-ol as a potential antimigraine agent. Bioorg Med Chem Lett. 1999;9:285–290.

Dahlof CG et al. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine:

a double-blind, parallel-group, randomized study. Cephalalgia. 2009;29(Suppl 2):7–16.

Goadsby PJ et al; Tonabersat TON-01-05 Study Group. Randomized, double-blind, placebo-controlled, proof-ofconcept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.

Cephalagia. 2009;29(7):742–750.

Srikiatkhachorn A et al. Pathophysiology of medication overuse headache-an update. Headache. 2014;54:204–

210.

Fumal A et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic

migraine. Brain. 2006;129:543–550.

Sarchielli P et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and

medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia. 2008;28:714–722.

Chatchaisak D et al. The role of calcitonin gene-related peptide on the increase in transient receptor potential

vanilloid-1 levels in trigeminal ganglion and trigeminal nucleus caudalis activation of rat. J Chem Neuroanat.

2013;47:50–56.

Evers S, Jensen R. Treament of medication overuse headache-guideline of the EFNS headache panel. Eur J

Neurol. 2011;18:1115–1121.

Tassorelli C et al. A consensus protocol for the management of medication-overuse headache: evaluation in a

multicentric, multinationalstudy. Cephalalgia. 2014;34(9):645–655.

Grande RB et al. Reduction in medication-overuse headache after short information. The Akershus study of

chronic headache. Eur J Neurol. 2011;18:129–137.

Diener HC et al; TOPMAT-MIG-201(TOPCHROME) Study Group. Topiramate reduces headache days in

chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–823.

Ekbom K, Hardebo JE. Cluster headache: aetiology, diagnosis and management. Drugs. 2002;62:61.

Manzoni GC et al. Late-onset cluster headache:some considerations about 73 cases. Neurol Sci. 2012;33(Suppl

1):S157–S159.

Nesbitt AD, Goadsby PJ. Cluster headache. BMJ. 2012;344:e2407.

May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet. 2005;366:843–855.

Bussone G. Cluster headache: from treatment to pathophysiology. Neurol Sci. 2008;29(Suppl 1):S1.

Bruera O et al. Plasma melatonin pattern in chronic and episodic headaches: evaluation during sleep and waking.

Funct Neurol. 2008;23(2):77–81.

Gooriah R et al. Evidence-based treatments for cluster headache. Ther Clin Risk Manag. 2015;11:1687–1696.

Bahra A et al. Cluster headache: a prospective clinical study in 230 patients with diagnostic implications.

Neurology. 2002;58:354–361.

Francis GJ et al. Acute and preventive pharmacologic treatment of cluster headache. Neurology. 2010;75:463.

Cittadini E et al. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebocontrolled, double-blind crossover study. Arch Neurol. 2006;63:1537.

Ashkenazi A, Schwedt T. Cluster headache: acute and prophylactic therapy. Headache. 2011;51:272.

Van Vliet JA et al. Intranasalsumatriptan in cluster headache: randomized placebo-controlled double-blind study.

Neurology. 2003;60(4):630–633.

Cohen A et al. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA. 2009;302:2451.

Nilsson Remahl AI et al. Hyperbaric oxygen treatment of active cluster headache: a double-blind placebocontrolled cross-over study. Cephalalgia. 2002;22(9):730–739.

Rapoport AM et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study

[published correction appears in Neurology. 2007;69:2029]. Neurology. 2007;69:821.

Matharu MS et al. Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind

crossover study. Ann Neurol. 2004;56:488–494.

Marks DR et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia.

1993;13:114.

Costa A et al. The effect of intranasal cocaine and lidocaine on nitroglycerin-induced attacks in cluster

headache. Cephalalgia. 2000;20:85–91.

190.

191.

192.

193.

194.

195.

196.

197.

198.

199.

200.

201.

202.

203.

204.

205.

206.

207.

208.

209.

210.

211.

212.

213.

214.

215.

216.

217.

218.

219.

Leone M et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo.

Neurology. 2000;54:1382.

May A et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias.

Eur J Neurol. 2006;13:1066–1077.

Blau JN, Engel HO. Individualizing treatment with verapamil for cluster headache patients. Headache.

2004;44:1013–1018.

Matharu MS et al. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs.

2003;63:1637–1677.

May A. Headaches with (ipsilateral) autonomic symptoms. J Neurol. 2003;250:1273–1278.

Bussone G et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache.

1990;30:411–417.

Ambrosini A et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a

double-blind placebo-controlled study. Pain. 2005;118:92.

Lainez MJ et al. Topiramate in the prophylactic treatment of cluster headache. Headache. 2003;43:784–789.

McGeeney BE. Topiramate in the treatment of cluster headache. Curr Pain Headache Rep. 2003;7:135–138.

Forderreuther S et al. Treatment of cluster headache with topiramate: effects and side-effects in five patients.

Cephalalgia. 2002;22:186–189.

Rozen TD. Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia. Headache.

2001;41(Suppl 1):25–33.

Leone M et al. Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia. 2003;23:1001–1002.